TITLE:

**BACTERICIDAL AND MEMBRANE DISRUPTION
ACTIVITIES OF THE EOSINOPHIL CATIONIC PROTEIN ARE LARGELY
RETAINED IN AN N-TERMINAL FRAGMENT**

AUTHORS :

Torrent, Marc¹; De la Torre, Beatriz G.²; Nogués, M.Victòria¹; Andreu, David²; and Boix, Ester^{1‡}

¹ Dpt. Bioquímica i Biologia Molecular, Fac. Biociències, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain

² Dpt. Ciències Experimentals i de la Salut, Universitat Pompeu Fabra- Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain

‡To whom correspondence should be addressed

RUNNING TITLE: Antimicrobial activity of ECP N-terminus

CORRESPONDING AUTHOR:

Ester Boix

Departament de Bioquímica i Biologia Molecular

Facultat de Biociències

Universitat Autònoma de Barcelona

08193 Cerdanyola del Vallès. Spain

E-mail: Ester.Boix@uab.es Phone: 34-93-5814147 Fax: 34-93-5811264

http://bioquimica.uab.es/paginas_cat/recerca_grups.php

KEYWORDS:

Antimicrobial peptides, host defense, electron microscopy, lipopolysaccharides, liposomes.

ABBREVIATIONS NOTE

BC (BODIPY TR Cadaverine), (5-(((4-(4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-indacene-3-yl)phenoxy)acetyl)amino)pentylamine, hydrochloride; DiSC₃(5), 3,3-dipropylthiacarbocyanine; AMPs, antimicrobial peptides; ECP, Eosinophil Cationic Protein; LPS, lipopolysaccharides; LTA, lipoteichoic acids; PMB, Polymyxin B; 1,2-dioleoyl-*sn*-glycero-3-phosphocholine, DOPC; 1,2 dioleoyl-*sn*-glycero-3-[phospho-rac-(1-glycerol)], DOPG; colony formation units (CFU), large unilamellar vesicles (LUV), circular dichroism (CD); IC₅₀, half inhibitory concentration; MIC, minimal inhibitory concentration; DLS, dynamic light scattering; TEM, transmission electron microscopy; SEM, scanning electron microscopy.

SUMMARY

Eosinophil cationic protein (ECP) is an eosinophil secretion protein with antipathogen activities involved in the host immune defense system. The bactericidal capacity of ECP relies on its action on both the plasma membrane and the bacterial wall. In a search for the structural determinants of ECP antimicrobial activity, we have identified an N-terminal domain (residues 1-45) that retains most of ECP's membrane-destabilizing and antimicrobial activities. Two sections of this domain, ECP(1-19) and ECP(24-45), have also been evaluated. All three peptides bind and partially insert into lipid bilayers, inducing aggregation of lipid vesicles and leakage of their aqueous content. In such an environment, the peptides undergo conformational change, significantly increasing their α -helix content. The bactericidal activity of the three peptides against *E. coli* and *S. aureus* has been assessed at both the cytoplasmic membrane and the bacterial envelope levels. ECP(1-45) and ECP(24-45) partially retain the native protein ability to bind lipopolysaccharides and electron microscopy reveals cell damage by both peptides. Interestingly, the *E. coli* cells agglutination activity of ECP is only retained by the longest segment ECP(1-45). Comparative results suggest a task distribution, whereby residues 1-19 would contribute to membrane association and destabilization, while the 24-45 region would be essential for bactericidal action. Results also indicate that ECP cytotoxicity is not uniquely dependant on its membrane disruption capacity, and that specific interactions at the bacteria wall are also involved.

INTRODUCTION

Host defense proteins and peptides of the innate immune system are potential candidates for chemotherapeutic development. Among those, antimicrobial peptides (AMPs) are characterized by a variety of primary and secondary structures [1] and by a broad spectra of activity. Their fast, non-specific mechanism of action [2], mostly at the plasma membrane and cell surface level, tends to make the development of resistant strains rather unlikely [3]. On the basis of these features, several native AMPs or their synthetic analogues have been proposed as alternatives to conventional antibiotics; and some of them are currently in clinical trials, mostly for topical applications [4].

Some AMPs are derived from host defense proteins by limited proteolysis that releases *in vivo* active fragments, often corresponding to the N or C terminus [5]. Proteolytic processing is very frequent in immunological cascade events, where local cleavage can release the active peptides in the area of infection or inflammation. There are also multiple examples of synthetic peptides corresponding to a protein N- or C-terminus that display antimicrobial activity [6]. Thus lactoferricin, a naturally occurring bactericidal peptide derived from the N-terminus of lactoferrin, is very effective against some antibiotic resistant strains [7]. Likewise, bactericidal permeability-increasing protein (BPI) is expressed in neutrophils and displays cytotoxicity against Gram-negative bacteria. A recombinant fragment corresponding to the BPI N- terminus is currently under phase III clinical trials [8]. Other examples of AMPs resulting from proteolysis include cathelicidins from neutrophils [9], and cryptdins, α -defensins secreted by intestinal Paneth cells, whose bactericidal activity requires activation of a precursor by a metalloprotease [10].

We are currently working on eosinophil cationic protein (ECP) as a model of the potential involvement of mammalian RNases in the host defense system. ECP is a secretory ribonuclease (RNase 3) found in the eosinophilic leukocyte and potentially involved in innate immunity. ECP can also be expressed at lower level by activated neutrophils. Although the role of eosinophils during infection is controversial, eosinophils are activated and selectively release their content at the inflammation areas [11]. Some authors have reported antimicrobial activities for eosinophils, and proposed a complementary action together with neutrophils during bacterial infections. Besides, the protein local secretion, which can harm the own host tissues, may also participate in immunoregulation and tissue remodeling processes [12, 13]. Although a wealth of structural and functional data have been reported, the physiological role of ECP remains elusive [14]. Its cytotoxic activity is effective against a wide range of pathogens, suggesting a relatively non-specific mechanism of action. Although there is no evidence of direct *in vivo* involvement of ECP in the host response to bacterial infection, ECP kills both Gram-negative and Gram-positive strains at a low micromolar range and its activity depends on its action both at the bacterial cell wall and cytoplasmic membrane levels [15-18]. ECP belongs to the vertebrate RNase A superfamily, several members of which are endowed with antimicrobial properties (Fig. 1S) [19-21], a family that may have started off playing a physiological role in the host immune system [22-24]. Interestingly, ECP antibacterial activity is not shared by eosinophil derived neurotoxin (EDN), a closely related eosinophil ribonuclease [25]. Antimicrobial RNases, as innate immune proteins with anti-infective and immunomodulatory properties, present substantial therapeutic potential in the drug development industry, both in the search of alternative antibiotics and for the treatment of inflammatory disorders.

In order to identify the structural determinants of ECP cytotoxic mechanism of action, we have searched the ECP sequence for potential active domains using a theoretical

approach to spot key antimicrobial regions (Torrent et al., unpublished results), and have identified a potentially active region at the N-terminus. To validate our hypothesis, we have synthesized three peptides representative of this region (Fig. 1) and assessed their properties both on a synthetic membrane model and on bacterial cell cultures.

RESULTS

Antimicrobial activity

Sequence analysis of ECP suggests that the N-terminus might contain an antimicrobial domain. Applying a predictive strategy based on a previous peptide library high-throughput screening results [26], a bactericidal propensity value was assigned to each amino acid (Torrent et al., submitted). Scanning on ECP spotted a main potential active region at the N-terminus (residues 30 to 45). To test this hypothesis, the full N-terminal domain, ECP(1-45), as well as two smaller representative peptides, ECP(1-19) and ECP(24-45), have been chosen for this study (Fig. 1). ECP(1-45) includes the first ECP α -helix elements ($\alpha 1$, $\alpha 2$ and $\alpha 3$) and the first $\beta 1$ region. The ECP(24-45) peptide spans the main predicted sequence and includes the Trp35-Arg36 residues previously identified to be determinant for cytotoxicity and membrane lysis activity [16, 27, 28]. The ECP(1-19) peptide, which corresponds to the first $\alpha 1$ domain, represents the ECP homolog of the S-peptide in RNase A [29].

The bactericidal properties of the three peptides against two representative Gram-negative and -positive strains (*E. coli* and *S. aureus*, respectively) have been compared with those of the full ECP sequence. Analysis of the half inhibitory concentration (IC_{50}) and the minimal inhibitory concentration (MIC) values (Table I) shows the 1-45 segment to be practically equivalent to the entire native sequence in terms of antimicrobial activity against both strains. Within the 1-45 segment, activity is shown to be mostly confined to residues 24-45, while the 1-19 peptide requires about 10-20 times higher concentrations to display significant bactericidal activity. As shown in Table 1, ECP and the three tested peptides displayed similar active ranges against both *E. coli* and *S. aureus*.

The bactericidal effects of the peptides on either strain have been further analyzed to better characterize their distinct properties. ECP can depolarize the cytoplasmic membrane of both *E. coli* and *S. aureus* cells [17]. The evaluation of the protein capacity to depolarize the bacteria cytoplasmic cell is an indirect method to assess its ability to interact at the bacteria surface and alter the inner membrane. Previous results on ECP depolarization capacity indicated that its activity is higher in the Gram-negative tested strain, probably as a consequence of the easier access of the protein to the cytoplasmic membrane. In fact, ECP can alter by itself the Gram-negative strain outer membrane structure [17]. We have now compared the protein depolarization capacity with the corresponding N-terminal peptides (Fig. 2). ECP(1-45) is the most active segment while ECP(24-45) retains an intermediate activity and ECP(1-19) shows the worst performance, as previously observed for the corresponding bactericidal values (Table I). However, significant differences between the two strains are also found. While in *E. coli* ECP(1-45) and ECP(24-45) have both intermediate activity and ECP(1-19) is quite inactive, in *S. aureus* ECP(1-45) is nearly equipotent with ECP, and ECP(1-19) is totally inactive.

For a better understanding of the cytotoxic activities of the peptides on bacteria we have analyzed their effects by electron microscopy. Potential damage on both the bacteria wall surface and the cytoplasmic membrane can be visualized by transmission electron

microscopy (TEM). In *E. coli*, ECP promotes outer membrane detachment, alteration of the overall cell shape and partial loss of cell content [17]. Comparison of the peptides with ECP confirms that both ECP(1-45) and ECP(24-45) are very active against *E. coli* (Fig. 3). TEM micrographs include many hypodense damaged cells with vacuolization, local outer membrane detachment and loss of characteristic baton-shaped morphology. In contrast, practically no damaged cells can be seen upon treatment with ECP(1-19). For *S. aureus* (Fig. 2S), TEM micrographs also show some hypodense cells for ECP(1-45) and ECP(24-45), although the overall damage is comparatively much more reduced for this strain. ECP(1-45) relative damage is similar to ECP, while ECP(24-45) is slightly less active. As above, no significant effect is visible for ECP(1-19).

Complementary analysis by SEM further illustrated the effect of the peptides on the bacterial surface. For ECP, previous data indicated a high ability to aggregate *E. coli* cells and to damage their wall envelope [17]. This cell agglutination ability is retained by ECP(1-45) (Fig. 3), while no aggregates are observed upon incubation with the shorter peptides ECP(24-45) and ECP(1-19). On the other hand, significant surface wall damage is patent for cells treated with both ECP(1-45) and ECP(24-45), while little effect is registered upon incubation with ECP(1-19). SEM micrographs of ECP-treated *S. aureus* cells did not reveal any aggregate, as already reported [17]. Surface wall damage for *S. aureus* cells is only mild compared to the treated *E. coli* cells and some local blebs appear. Cells incubated with ECP(1-45) show nearly the same pattern, while with ECP(24-45) wall damage is quite mild, and undetectable with ECP(1-19) (Fig. 2S). Outer membrane detachment, visualized by electron microscopy, is considered to be related to ECP uncommonly high ability to bind lipopolysaccharides (LPS), the main component of Gram-negative bacterial surfaces, and its antigenic portion, the lipid A [17]. We have now compared the LPS binding capacity of ECP and its N-terminal fragments. A decreasing order of LPS binding abilities, from ECP(1-45) to ECP(1-19) is registered (see Table II and Fig. 3S). The displacement ability of ECP(1-45) is considerably lower than that of ECP, but still high if compared with the positive control polymyxin B (Fig. 3S). On the contrary, ECP(1-19) does not have any significant affinity to LPS. The LPS binding process can also be followed by the analysis of the intrinsic fluorescence spectra (see Table II). The recorded blue shifts suggest that Trp residues are involved in the interaction and that Trp35 might be the one which mostly alters its environment upon binding. On the other hand, while the native protein does not modify its overall structure upon LPS binding, as assessed by CD spectra, we observe significant changes for the peptides, with an increase in their secondary structure content (Fig. 6). The near UV spectra indicate that changes at the aromatic residues local environments take place in the presence of LPS. A careful inspection reveals that while ECP(1-19) does not modify significantly its overall profile, both ECP(1-45) and ECP(24-45) register an altered profile. In particular, ECP(1-45) shifts drastically the bands in the characteristic ranges for Tyr and Trp, suggesting the involvement of Tyr33 and Trp35 exposed residues in the LPS binding. Interestingly, both ECP(1-45) and ECP(24-45) peptide far UV spectra in the presence of LPS indicate a much more structured conformation upon binding (Fig. 6).

Additionally, in order to identify potential interactions between the protein and the N-terminal peptides at the Gram-positive bacteria surface, we have also analyzed the changes at the intrinsic fluorescence spectra in the presence of lipoteichoic acids (LTA). Electrostatic interactions between the polypeptide cationic residues and the negative charged groups of LTA are expected. Results confirmed the binding of LTA and the contribution of Trp residues (Table II). Pronounced shifts are mainly recorded for ECP(1-45) and ECP (24-45) peptides, with comparable values, while the blue shift

corresponding to the ECP(1-19) is only minor, suggesting the involvement of Trp35 in the interaction.

Interaction with lipid bilayers

The correlation between ECP cytotoxic activity and its membrane destabilizing capacity has been previously reported [27, 28]. Detailed analysis of ECP action using large and giant unilamellar vesicles as membrane models revealed aggregation and leakage activities at a nanomolar range [16, 18]. In the present work, we have characterized the interaction of ECP N-terminal peptides with LUV vesicles made up of DOPC/DOPG phospholipids.

The intrinsic fluorescence signals of the peptides were first analyzed. ECP includes two Trp residues, Trp10 and Trp35, both present in the studied ECP peptides, that have been classified into different spectral classes [30]. Comparison of ECP with single Trp mutants indicates that most of the blue shift in the fluorescence spectrum is due to the association of solvent-exposed Trp35 with the lipid bilayer [16]. The intrinsic fluorescence spectra of the peptides (Fig. 4S) indicate that, as expected, both Trp residues are now much more solvent-exposed than in their respective locations within the protein. Of the two, Trp10 is the residue experiencing a more pronounced change, from a buried location in ECP [16] to a more exposed position in ECP(1-19).

When the peptide spectra are recorded in the presence of the DOPC/DOPG LUVs, a significant blue shift is observed in all cases, confirming the interaction with the lipid bilayer. Shifts for ECP(24-45) and ECP(1-45) are more pronounced than for ECP(1-19), suggesting that Trp35 does undergo a more pronounced change on its microenvironment when the peptides associate to the lipid bilayers. In fact, the similarity between spectra of ECP(24-45) and ECP(1-45) suggests that Trp10 contribution to the final signal is minor.

The interaction with lipid bilayers has been further investigated by fluorescence quenching experiments using brominated phospholipids. For that purpose, LUVs made up of DOPC:DOPG with PC dibromo derivatives at several positions remote from the head group (6,7; 9,10 and 11,12, respectively) have been prepared. This methodology allows an estimation of the degree of peptide insertion into the lipid bilayers. The quenching efficiency of the differently brominated lipids has been recorded by comparing the respective fluorescence quenching slopes. For all peptides, the presence of either Trp10 or Trp35 has allowed to monitor changes upon membrane interaction. The Stern- Volmer quenching slopes show a steep decrease from the 6,7- to the 11,12-dibrominated LUVs, indicating a diminishing interaction between the Trp residues and the bromine-labeled phospholipid (Fig. 5S). From these data, an average insertion of ca. 10 Å (from the bilayer center) can be estimated for the Trp residues of both ECP(24-45) and ECP(1-45), similar to ECP [16], while a slightly deeper insertion (ca. 8Å) is found for the ECP(1-19) peptide (Fig. 4).

Another way to evaluate lipid bilayer destabilization is determining the ability to aggregate lipid vesicles and to trigger the leakage and release of aqueous content. Thus, ECP promotes the release of encapsulated ANTS/DPX at 1/300 protein/lipid ratio and above [16]. In tune with above trends, the leakage ability of ECP(1-45) is similar to ECP, that of ECP(24-45) is slightly lower, while ECP(1-19) requires much higher peptide/lipid ratios to induce significant leakage (Fig. 5.A).

Liposome aggregation can also be monitored by the increase of scattering intensity at 470 nm. By this method, ECP has detectable LUV aggregation above 1/1500 protein/lipid molar ratio [16], which is mostly retained by ECP(1-45) but somehow

surprisingly lost in the ECP(24-45), while partial aggregating behavior is noted for ECP(1-19) (Fig. 5.B).

Finally, we have used circular dichroism (CD) to investigate the conformational changes brought about by peptide- membrane interaction (Fig. 6). The CD spectrum of ECP in aqueous solution has been reported [31], with the inferred secondary structure values showing some deviation from those derived from X-ray crystallography [32]. Those differences were mainly attributed to the contribution of aromatic amino acid side chains to the spectral profile. Comparison of the near UV spectra of ECP and the peptides (Fig. 6) reveals significant changes at the aromatic residues local environment for ECP(1-45) and ECP(24-45).

We have also analyzed the far UV spectra for ECP and the derived peptides in the absence and presence of SDS (Fig. 6). ECP data indicates that no overall conformation changes have taken place. In contrast, for the three peptides some significant differences were observed. SDS induced mainly the transition to more structured conformations for the three peptides, where a reduction of the β -sheet content and a significant increase in the α -helical content is registered. Thus we can conclude that when exposed to a lipid environment the peptides undergo conformational reorganization, increasing considerably their structured content. Comparison of the α -helix content for each peptide indicates an increase of 25, 35 and 70% for ECP(1-19), ECP(24-45) and ECP(1-45) respectively. This is in tune with the respective abilities to disrupt lipid bilayers (Fig. 5.A). On the other hand, prediction of potential transmembrane segments using the MPEx software identifies a segment from residues 9 to 27 with a high tendency to form α -helix in a lipid environment. This might explain why the peptide with the highest activity on lipid bilayers is ECP(1-45), which includes this segment in its entirety.

DISCUSSION

ECP is an eosinophil-secreted protein involved in inflammation processes with diverse antipathogen properties [14, 33]. In previous works we have characterized its bactericidal activity, and identified some structural determinants for its cytotoxic capacity [16-18, 28]. ECP diverged from the other eosinophil RNase, EDN, under an unusual evolutive pressure and acquired a higher cationicity and cytotoxicity [34]. We have now identified an N-terminal region that retains both the bactericidal and membrane-disrupting activities of ECP. The selected 1-45 segment fulfills the common structural- chemical criteria for AMPs [1, 35, 36]. It includes a high number of Arg residues which confer the three synthetic peptides a net positive charge [+2, +5 and +8 for ECP(1-19), ECP(24-45) and ECP(1-45), respectively] as well as a high pI (predicted as 12, 11.5 and 11.9). On the other hand, the studied N- terminus includes two Cys residues, which were substituted in the synthetic peptides by Ser to avoid potential formation of intra or inter disulfide bridges. Although the peptides cannot reproduce the full scenario in the context of the disulfide- bonded protein structure, the use of synthetic peptides, with Cys substitutions or deletions, is an useful approach, as reported for other antimicrobial proteins [37]. In fact, some antimicrobial proteins do retain activity at their denatured state [6]. We can also find the report of an antimicrobial RNase A homolog, the salmon RNase, which preserves activity when fully denatured [20]. Moreover, the characterization of protein derived peptides was also successfully applied to the avian leukocyte RNase A homologues (Fig. 1S), where one of the peptides outside the protein scaffold retained the bactericidal activity [38]. A cationic cluster at the N-terminus was also identified for the skin derived RNase 7, another

human RNase A homolog (Fig. 1S) that contributes to the innate immunity at the skin chemical barrier [39, 40].

Comparison of the bactericidal and membrane-destabilizing activities of ECP and the three synthetic peptides indicates that the ECP N-terminus retains part of the sequence determinants involved at the different levels of ECP's cytotoxic capacity. The longest 1-45 peptide displays nearly all the bactericidal activity of the whole protein against *E. coli* and *S. aureus* strains, and partially retains the LPS binding and depolarization abilities. Additionally, ECP(1-45) has almost the same membrane interaction capacity than ECP, with nearly equivalent leakage and liposome aggregation activities. For its part, the inner ECP(24-45) peptide can partially but not fully reproduce the bactericidal and membrane destabilization capacities of the intact protein and the N-terminal ECP(1-19) short peptide has almost completely lost its toxicity for bacterial cells.

Altogether, the results obtained reveal once again that membrane disruption cannot by itself explain the toxicity of ECP towards bacterial cells. Besides, the observed differences on the activity against Gram-negative and Gram-positive strains also suggest the involvement of strain- specific determinants in the killing events. Electron microscopy illustrates diverse abilities of the peptides at the bacterial wall surface. Similar bactericidal activities do not readily translate to bacteria wall damage, suggesting that cell viability is lost before any cell surface destruction is visualized. Although ECP and its derived peptides are bactericidal on both *E. coli* and *S. aureus*, bacterial wall damage is much more pronounced on the Gram-negative strain. ECP shows a specific capacity to destroy the *E. coli* outer membrane and to agglutinate the cells [17], which is only retained by the full 1-45 fragment.

The propensity of ECP and its derived peptides to bind lipid bilayers may also be facilitated by their hydrophobicity and aggregation tendency. We used the *Aggrescan* software [41] to screen the ECP sequence for the presence of hydrophobic patches that can favour aggregation. One such sequence is found at the ECP N-terminus (residues 8 to 16), and is not present in the other eosinophil RNase (EDN). An N-terminal aggregation domain is also identified in the skin-derived RNase 7, though not in other screened human RNases (results not shown). An exposed hydrophobic patch may promote both protein- protein and also protein-lipid bilayer interactions. The fact that ECP(1-19) partially retains a lipid aggregation ability, while the internal segment ECP(24-45) does not, also supports the presence of a potential "aggregation-promoting" domain at the ECP N-terminus end.

For its part, the other short peptide ECP(24-45) seems to include a key region for bactericidal action, as well as for specific binding to the bacteria wall. Both ECP(1-45) and ECP(24-45) retain part of ECP's affinity for LPS, where Tyr33 and Trp35 residues might participate in the interaction. Recent results on ECP heparin binding affinity indicate that charged and aromatic residues in the 34-38 region are involved in this selective ability [42], providing a key domain for the protein anchoring to the cell surface. Recent work by Döring and coworkers [43] on the Tyr nitration process activated during eosinophil maturation identified in ECP a unique Tyr nitration at residue 33, and suggested that Tyr nitration may modulate ECP aggregation and/or its interaction with other eosinophil proteins.

In view of all above, we submit that the 1-45 sequence of ECP embraces a main protein functional domain. We have proven that the ECP(1-45) peptide reproduces most of ECP's antimicrobial properties. The inner ECP(24-45) sequence retains the key bactericidal region, but loses some of ECP's membrane destabilizing capacities. One can plausibly propose that the first 19 residues are also necessary, either for preserving native-like conformation, or for promoting aggregation or both. While devoid of

significant bactericidal action, this 1-19 region retains membrane-destabilizing properties, in tune with data suggesting that it includes an aggregation patch.

In any event, ECP-derived peptides can provide a model, as a novel source of AMPs as alternative antibiotics against resistant strains. The ECP *E. coli* cells agglutinating activity is indeed a selected property in the search of alternative antibiotics, as a mechanism to induce bacteria clearance by the host phagocytic cells [44]. Given the pharmaceutical interest on the development of new LPS binders for treatment of immune disorders, the partial LPS-binding ability at the 24-45 stretch also offers a starting template for the design of new peptide-derived immunomodulator drugs.

MATERIALS AND METHODS

Materials

1,2-dioleoyl-*sn*-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-*sn*-glycero-3-[phospho-*rac*-(1-glycerol)] (DOPG); 1-palmitoyl-2-stearoyl-(6,7, 9,10, and 11,12)-dibromo-*sn* glycero-3-phosphocholine (6,7-diBrPC, 9,10-diBrPC, and 11,12-diBrPC) were from Avanti Polar Lipids (Birmingham, AL). 8-aminonaphthalene-1,3,6-trisulfonic acid disodium salt (ANTS) and *p*-xylene-bis-pyridinium bromide (DPX) were from Molecular Probes, Invitrogen (Carlsbad, CA). Bovine pancreatic ribonuclease A, type XII-A; Polymyxin B sulfate, lipoteichoic acids from *S. aureus*, and LPS from *E. coli* serotype 0111:B4 were purchased from Sigma-Aldrich (St. Louis, MO). BODIPY TR cadaverine, BC (5-(((4-(4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-indacene-3-yl)phenoxy)acetyl)amino)pentylamine, hydrochloride;) and 3,3-dipropylthiacarbocyanine (diSC₃(5)) were purchased from Molecular Probes (Eugene, OR). PD-10 desalting columns with Sephadex G-25 were from Amersham Pharmacia Biotech, Uppsala, Sweden. *Escherichia coli* BL21DE3, Novagen (Madison, WI) and *Staphylococcus aureus* 502 A, ATCC (Rockville, MD) strains were used.

Peptides

Peptide ECP(1-19) was obtained from NeoMPS (Strasbourg, France). ECP(24-45) and ECP(1-45), with Cys residues at positions 23 and 37 replaced by Ser, were prepared by Fmoc solid phase peptide synthesis methods [45]. All peptides were purified by HPLC to ca. 95% homogeneity and satisfactorily characterized by MALDI-TOF mass spectrometry. Further experimental details can be found in the Supplementary material file (Figs. S6-S8).

Expression and Purification of ECP

Wild-type ECP was obtained from a human ECP synthetic gene [46]. Protein expression in the *E. coli* BL21(DE3) strain, folding of the protein from inclusion bodies and the purification steps were carried out as previously described [46].

IC₅₀ determination

Antimicrobial activity was expressed as the half inhibitory concentration (IC₅₀). IC₅₀ of each peptide was determined from 2 independent experiments performed in triplicate for each peptide concentration. Peptides were dissolved in Na₂HPO₄ phosphate buffer, 10 mM, pH 7.5 and serially diluted from 0.2 μM to 10 μM. Bacteria were incubated at 37 °C overnight in LB and diluted to give approximately 5x10⁵ CFU/ml. In each assay peptide solutions were added to each bacteria dilution, incubated for 4 hours and samples were plated on Petri dishes and incubated at 37°C overnight. The colony

forming units (CFU) in each Petri dish was counted, the average and the standard error calculated and represented in a semi –logarithmic plot.

MIC determination

Antimicrobial activity was expressed as the minimal inhibitory concentration (MIC), which is defined as the lowest concentration of peptides that completely inhibits microbial growth. MIC of each peptide was determined from 2 independent experiments performed in triplicate for each peptide concentration. Peptides were dissolved in Na₂HPO₄ phosphate buffer, 10 mM, pH 7.5 and serially diluted from 0.2 μ M to 100 μ M. Bacteria were incubated at 37 °C overnight in LB and diluted to give approximately 5×10^5 CFU/ml. In each assay peptide solutions were added to each bacteria dilution, incubated for 4 hours and samples were plated on Petri dishes and incubated at 37°C overnight.

Liposome preparation

Large unilamellar vesicles (LUV) of a defined size (about 200 nm) were prepared from a vacuum-drying lipids chloroform solution by extrusion through 800, 400 and 200 nm polycarbonate membranes as previously described [16]. The lipid suspension was frozen and thawed several times prior extrusion. Liposomes containing DOPC/DOPG (3:2 molar ratio) were obtained. A 1 mM stock solution of liposome suspension in 10 mM Tris-HCl, 0.1 M NaCl, pH 7.4 was prepared.

Fluorescence measurements

Tryptophan (Trp) fluorescence emission spectra were recorded using a 280nm excitation wavelength. Slits were set at 2 nm for excitation and 5-10 nm for emission. Emission spectra were recorded from 300 to 400 nm at a scan rate of 60 nm/min, in a 10 x 10 mm cuvette with stirring immediately after sample mixing. Protein and peptide spectra at 0.5 μ M in 10 mM Hepes, pH 7.4 buffer were obtained at 25 °C in the absence and presence of 200 μ M liposome suspension, 200 μ M LPS (assuming a 90000 g/mol molecular weight) or 200 μ M LTA (calculated from a 2200 MW reference value). Fluorescence measurements were performed on a Cary Eclipse Spectrofluorimeter. Spectra in the presence of liposomes were corrected for light scattering, by subtracting the corresponding LUV background. For each condition 3 spectra were averaged. The fluorescence spectra were also calculated as a function of the frequency scale (wave number) and adjusted using a log-normal function as detailed previously [16].

Depth-dependent fluorescence quenching experiments using labelled brominated lipids

Quenching of protein Trp residues by brominated lipids was introduced to analyze the relative location of both Trp10 and Trp35 residues upon membrane interaction. LUV of DOPC/DOPG (3:2 molar ratio) were prepared as previously described [16], containing either (6,7)-, (9,10)-, or (11,12)- Br₂-PC. Brominated lipids were mixed at increasing percentage from 20% up to 80% with unlabelled DOPC/DOPG vesicles. The emission fluorescence spectra were recorded at 25°C using the following conditions: 10 mM Tris-HCl, pH 7.4, buffer, 0.5 μ M protein concentration and 200 μ M liposome concentration, excitation wavelength of 280 nm, excitation and emission slits set to 2 and 10 nm respectively. For each condition 3 spectra were averaged. The quenching efficiency of brominated lipids on protein Trp fluorescence was determined by calculating the area under the fluorescence spectra in range of 320 to 380 nm. Relative fluorescence intensities (F_0/F) were compared, where F_0 is the fluorescence intensity in the absence

of quencher. To calculate the depth of insertion of the protein in the lipid bilayer the distribution analysis (DA) was employed, as previously detailed [16].

ANTS/DPX liposome leakage assay

The ANTS/DPX liposome leakage fluorescence assay was performed as described previously [16, 28]. Briefly, a unique population of large unilamellar vesicles (LUV) of DOPC/DOPG (3:2 molar ratio) lipids was obtained containing 12.5 mM ANTS, 45 mM DPX, 20 mM NaCl, 10 mM Tris-HCl, pH 7.5. The ANTS/DPX liposome suspension was diluted to 30 μ M final concentration and was incubated at room temperature in the presence of the ECP or the synthetic peptides. The leakage activity was assayed at different polypeptide concentrations, up to 8 μ M, by following the release of the liposome content. Fluorescence was measured using a 386 nm excitation wavelength and 535 nm emission wavelength. Slits were set at 5 nm and 10 nm for excitation and emission respectively. The percentage of leakage (%L) produced by the proteins after 1 h of incubation with the liposomes was calculated with the following equation: (%L) = $100(F_p - F_0)/(F_{100} - F_0)$; where F_p is the final fluorescence intensity after addition of the protein (1 h), F_0 and F_{100} are the fluorescence intensities before addition of the protein and after addition of 0.5% Triton X100. For each protein concentration three calculated leakage values were averaged. Leakage could not be quantified for those samples where the assay conditions trigger the LUV precipitation, as LUV samples incubated with high ECP protein concentrations.

LUV liposome aggregation

Aggregation of LUV lipid vesicles was monitored by measuring the scattering intensity with the excitation and emission wavelengths set at 470 nm using a Cary Eclipse spectrofluorimeter and cuvettes with an optical path of 1 cm. Prior to the addition of ECP and peptides, the vesicles were allowed to equilibrate for 15 min at room temperature. The buffer used was 10 mM HEPES, pH 7.4. Final assay conditions were: 200 μ M lipid concentration and from 0.04 to 4 μ M polypeptide range concentration, in 10 mM HEPES, pH 7.4 buffer. After 30 min of incubation at room temperature, the signal was read at 90° from the excitation beam with slits at 5 and 10 nm.

Circular dichroism spectroscopy

The far-UV circular dichroism (CD) spectra were collected with a JASCO J-715 spectropolarimeter. Spectra were recorded from 250 up to 190 nm, at 1 nm intervals, 1 nm bandwidth, with a scan speed of 10 nm/min, at 25°C. 0.2 cm pathlength cuvettes were used. Mean-residue ellipticity $[\theta]$ (deg cm² dmol⁻¹) was calculated using the formula:

$$[\theta] = \frac{\theta(MRW)}{10cl}$$

where MRW is the mean residue molecular weight of the protein, c is the protein concentration and l is the cell path length. Data of 4 consecutive scans was averaged and a linear smoothing from each 5 consecutive measurements was applied. ECP and peptides spectra in the absence and presence of SDS and LPS were recorded. 4-8 μ M ECP or peptide concentrations diluted in phosphate buffer 5 mM, pH 7.5, and 1 mM SDS and 1 mM LPS (assuming a 90000 g/mol molecular weight) concentration were used. Samples were centrifuged for 5 min at 10,000 g before use. For near-UV CD, spectra were recorded from 340 up to 255 nm, at 1 nm intervals, 1 nm bandwidth, with

a scan speed of 10 nm/min, at 25°C and 1 cm pathlength cuvettes were used. Data of 4 consecutive scans was averaged. ECP and peptides spectra in the absence and presence of LPS were recorded. 80-100 µM ECP or peptide concentrations diluted in phosphate buffer 5 mM, pH 7.5, and 1 mM LPS (assuming a 90000 g/mol molecular weight) concentration were used. Percentage of each secondary structure was estimated using the JASCO software, based on the calculation method described by Yang and coworkers [47].

Bioinformatic analysis tools for peptide characterization

Physicochemical properties of peptides (pI and net charge) were predicted using the Swiss-Prot expasy server (<http://www.expasy.ch/sprot/>). Transmembrane- prediction domain analysis was performed using the Membrane Protein Explorer server (MPEx; <http://blanco.biomol.uci.edu/mpex>). Sequences with aggregation propensity were predicted using the Aggrescan server [41].

Bacterial cytoplasmic membrane depolarization assay

Membrane depolarization was monitored as previously described [17], using the DiSC3(5) lipophilic dye that changes its fluorescence intensity in response to changes in transmembrane potential. *E. coli* and *S. aureus* cells were grown to mid-exponential phase and resuspended in 5 mM Hepes-KOH, 20 mM glucose, and 100 mM KCl at pH 7.2 to an OD₆₀₀ of 0.05. DiSC3(5) was added. Changes in the fluorescence due to the alteration of the cytoplasmic membrane potential were continuously monitored at 20 °C by fluorescence emission at 670 nm using an excitation wavelength of 620 nm. When the dye uptake was maximal, as indicated by a stable reduction in the fluorescence because of quenching of the accumulated dye at the membrane, polypeptide samples were added at a final concentration of 4 µM. All conditions were assayed in duplicate. The time necessary to reach a stabilized maximum fluorescence reading was recorded for each condition.

Fluorescent probe displacement assay for lipopolysaccharide binding

Lipopolysaccharide (LPS) binding was assessed using the fluorescent probe BODIPY TR cadaverine (BC) as previously described [17]. BC binds strongly to native LPS, specifically recognizing the Lipid A portion. LPS binding assays were carried out in 5 mM Hepes buffer, pH 7.5. The displacement assay was performed by the addition of 1-2 µl aliquots of a stock solution of ECP and peptides to 1 ml of a continuously stirred mixture of LPS at 10 µg/ml and BC (10 µM). The BC excitation wavelength was 580 nm and emission wavelength was 620 nm. Excitation and emission slits were set at 2.5 nm and 20 nm, respectively. Final values correspond to an average of 4 replicates. Quantitative effective displacement values (ED₅₀) were calculated. The ED₅₀ was computed at the midpoint of the fluorescent signal versus the protein concentration of the displacement curve by a curve-fitting of the data to the equation

$$OF = \frac{F_0 - F}{F_0 - F_{max}}$$

where *OF* is the occupancy factor, *F*₀ the fluorescence intensity of BC alone, *F*_{max} is the intensity in the presence of LPS at a saturation concentration and *F* the intensities of the LPS:BC mixtures at each displacer concentrations. Polymyxin B (PMB) and RNase A were used as positive and negative controls, respectively.

Scanning electron microscopy (SEM)

One-ml cultures of *E. coli* and *S. aureus* were grown at 37 °C to mid-exponential phase (OD₆₀₀ of 0.4) and incubated with 10 µM of ECP and the derived peptides in phosphate-buffered saline (PBS) at room temperature. Sample aliquots were taken up to 4 h of incubation and prepared for SEM analysis as previously described [17]. The micrographs were viewed at 15 kV accelerating voltage in a Hitachi S-570 scanning electron microscope, and a secondary electron image of cells for topography contrast was collected at several magnifications.

Transmission Electron Microscopy (TEM).

Mid-logarithmic phase *E. coli* and *S. aureus* cells (OD₆₀₀ ~ 0.4) were incubated with 10 µM ECP and peptides for 4 h. After treatment, bacterial pellets were prefixed with 2.5% glutaraldehyde and 2% paraformaldehyde in 0.1 M cacodylate buffer at pH 7.4 for 2 h at 4 °C and post-fixed in 1% osmium tetroxide buffered in 0.1 M cacodylate at pH 7.4 for 2 h at 4 °C. The samples were dehydrated in acetone (50, 70, 90, 95, and 100%). The cells were immersed in EPON resin, and ultrathin sections were examined in a JEOL JEM 2011 microscope (Jeol Ltd., Tokyo, Japan).

ACKNOWLEDGMENTS

Scanning electron microscopy was performed at the Servei de Microscopia of the Universitat Autònoma de Barcelona (UAB). We thank Francisca Cardoso and Francesc Bohils for their assistance in electron micrography preparation. Fluorescence assays were done at the Laboratori d'Anàlisi i Fotodocumentació, Fac. Biociències, UAB. CD spectra were recorded at the Servei d'Anàlisi Química, Fac. Ciències, UAB. This project was funded by a grant from Ministerio de Educación y Cultura (Grants BMC2003-08485-C02-01 and BFU2006-15543-C02-01) and by the Fundació La Marató de TV3 (TV3-031110). M.T. was the recipient of a predoctoral fellowship from the Generalitat de Catalunya. Work at Universitat Pompeu Fabra was supported by the Spanish Ministries of Health (Fondo de Investigaciones Sanitarias grant PI040885), Education and Science (BIO2005-07592-CO2-02 and PET2006-00139-00), and by Generalitat de Catalunya (SGR00494).

REFERENCES

- 1 Powers, J. P. and Hancock, R. E. (2003) The relationship between peptide structure and antibacterial activity. *Peptides* **24**, 1681-1691
- 2 Lohner, K. and Blondelle, S. E. (2005) Molecular mechanisms of membrane perturbation by antimicrobial peptides and the use of biophysical studies in the design of novel peptide antibiotics. *Comb Chem High Throughput Screen* **8**, 241-256
- 3 Rivas, L., Luque-Ortega, J. R. and Andreu, D. (2008) Amphibian antimicrobial peptides and Protozoa: Lessons from parasites. *Biochim Biophys Acta*
- 4 Hancock, R. E. and Sahl, H. G. (2006) Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. *Nat Biotechnol* **24**, 1551-1557
- 5 Gudmundsson, G. H. and Agerberth, B. (1999) Neutrophil antibacterial peptides, multifunctional effector molecules in the mammalian immune system. *J Immunol Methods* **232**, 45-54
- 6 During, K., Porsch, P., Mahn, A., Brinkmann, O. and Gieffers, W. (1999) The non-enzymatic microbicidal activity of lysozymes. *FEBS Lett* **449**, 93-100
- 7 Nibbering, P. H., Ravensbergen, E., Welling, M. M., van Berkel, L. A., van Berkel, P. H., Pauwels, E. K. and Nuijens, J. H. (2001) Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria. *Infect Immun* **69**, 1469-1476
- 8 Canny, G. and Levy, O. (2008) Bactericidal/permeability-increasing protein (BPI) and BPI homologs at mucosal sites. *Trends Immunol* **29**, 541-547
- 9 Zanetti, M., Gennaro, R. and Romeo, D. (1995) Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. *FEBS Lett* **374**, 1-5
- 10 Ayabe, T., Satchell, D. P., Pesendorfer, P., Tanabe, H., Wilson, C. L., Hagen, S. J. and Ouellette, A. J. (2002) Activation of Paneth cell alpha-defensins in mouse small intestine. *J Biol Chem* **277**, 5219-5228
- 11 Hogan, S. P., Rosenberg, H. F., Moqbel, R., Phipps, S., Foster, P. S., Lacy, P., Kay, A. B. and Rothenberg, M. E. (2008) Eosinophils: biological properties and role in health and disease. *Clin Exp Allergy* **38**, 709-750
- 12 Zagai, U., Skold, C. M., Trulsson, A., Venge, P. and Lundahl, J. (2004) The effect of eosinophils on collagen gel contraction and implications for tissue remodelling. *Clin Exp Immunol* **135**, 427-433
- 13 Gomes, I., Mathur, S. K., Espenshade, B. M., Mori, Y., Varga, J. and Ackerman, S. J. (2005) Eosinophil-fibroblast interactions induce fibroblast IL-6 secretion and extracellular matrix gene expression: implications in fibrogenesis. *J Allergy Clin Immunol* **116**, 796-804
- 14 Boix, E., Torrent, M., Sánchez, D. and Nogués, M. V. (2008) The Antipathogen Activities of Eosinophil Cationic Protein. *Current Pharm Biotec* **9**, 141-152
- 15 Lehrer, R. I., Szklarek, D., Barton, A., Ganz, T., Hamann, K. J. and Gleich, G. J. (1989) Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. *J Immunol* **142**, 4428-4434
- 16 Torrent, M., Cuyas, E., Carreras, E., Navarro, S., Lopez, O., de la Maza, A., Nogues, M. V., Reshetnyak, Y. K. and Boix, E. (2007) Topography studies on the membrane interaction mechanism of the eosinophil cationic protein. *Biochemistry* **46**, 720-733

- 17 Torrent, M., Navarro, S., Moussaoui, M., Nogues, M. V. and Boix, E. (2008) Eosinophil cationic protein high-affinity binding to bacteria-wall lipopolysaccharides and peptidoglycans. *Biochemistry* **47**, 3544-3555
- 18 Torrent, M., Sánchez, D., Buzón, V., Nogués, M. V., Cladera, J. and Boix, E. (in press) Comparison of the membrane interaction mechanism of two antimicrobial RNases: RNase 3/ECP and RNase 7. *BBA Biomembranes*
- 19 Boix, E. and Nogues, M. V. (2007) Mammalian antimicrobial proteins and peptides: overview on the RNase A superfamily members involved in innate host defence. *Mol Biosyst* **3**, 317-335
- 20 Pizzo, E., Varcamonti, M., Di Maro, A., Zanfardino, A., Giancola, C. and D'Alessio, G. (2008) Ribonucleases with angiogenic and bactericidal activities from the Atlantic salmon. *Febs J* **275**, 1283-1295
- 21 Hooper, L. V., Stappenbeck, T. S., Hong, C. V. and Gordon, J. I. (2003) Angiogenins: a new class of microbicidal proteins involved in innate immunity. *Nat Immunol* **4**, 269-273
- 22 Cho, S. and Zhang, J. (2007) Zebrafish ribonucleases are bactericidal: implications for the origin of the vertebrate RNase A superfamily. *Mol Biol Evol* **24**, 1259-1268
- 23 Rosenberg, H. F. (2008) RNase A ribonucleases and host defense: an evolving story. *J Leukoc Biol* **83**, 1079-1087
- 24 Pizzo, E. and D'Alessio, G. (2007) The success of the RNase scaffold in the advance of biosciences and in evolution. *Gene* **406**, 8-12
- 25 Rosenberg, H. F. (2008) Eosinophil-derived neurotoxin/ RNase 2: connecting the Past, the Present and the Future. *Current Pharm Biotec.* **9**, 135-140
- 26 Hilpert, K., Volkmer-Engert, R., Walter, T. and Hancock, R. E. (2005) High-throughput generation of small antibacterial peptides with improved activity. *Nat Biotechnol* **23**, 1008-1012
- 27 Carreras, E., Boix, E., Navarro, S., Rosenberg, H. F., Cuchillo, C. M. and Nogues, M. V. (2005) Surface-exposed amino acids of eosinophil cationic protein play a critical role in the inhibition of mammalian cell proliferation. *Mol Cell Biochem* **272**, 1-7
- 28 Carreras, E., Boix, E., Rosenberg, H. F., Cuchillo, C. M. and Nogues, M. V. (2003) Both aromatic and cationic residues contribute to the membrane-lytic and bactericidal activity of eosinophil cationic protein. *Biochemistry* **42**, 6636-6644
- 29 Marshall, G. R., Feng, J. A. and Kuster, D. J. (2008) Back to the future: ribonuclease A. *Biopolymers* **90**, 259-277
- 30 Reshetnyak, Y. K., Koshevnik, Y. and Burstein, E. A. (2001) Decomposition of protein tryptophan fluorescence spectra into log-normal components. III. Correlation between fluorescence and microenvironment parameters of individual tryptophan residues. *Biophys J* **81**, 1735-1758
- 31 Nikolovski, Z., Buzon, V., Ribo, M., Moussaoui, M., Vilanova, M., Cuchillo, C. M., Cladera, J. and Nogues, M. V. (2006) Thermal unfolding of eosinophil cationic protein/ribonuclease 3: a nonreversible process. *Protein Sci* **15**, 2816-2827
- 32 Boix, E., Leonidas, D. D., Nikolovski, Z., Nogues, M. V., Cuchillo, C. M. and Acharya, K. R. (1999) Crystal structure of eosinophil cationic protein at 2.4 Å resolution. *Biochemistry* **38**, 16794-16801
- 33 Venge, P., Bystrom, J., Carlson, M., Hakansson, L., Karawaczyk, M., Peterson, C., Seveus, L. and Trulsson, A. (1999) Eosinophil cationic protein (ECP):

- molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. *Clin Exp Allergy* **29**, 1172-1186
- 34 Zhang, J., Rosenberg, H. F. and Nei, M. (1998) Positive Darwinian selection after gene duplication in primate ribonuclease genes. *Proc Natl Acad Sci U S A* **95**, 3708-3713
- 35 Brown, K. L. and Hancock, R. E. (2006) Cationic host defense (antimicrobial) peptides. *Curr Opin Immunol* **18**, 24-30
- 36 Andreu, D. and Rivas, L. (1998) Animal antimicrobial peptides: an overview. *Biopolymers* **47**, 415-433
- 37 Bulet, P., Stocklin, R. and Menin, L. (2004) Anti-microbial peptides: from invertebrates to vertebrates. *Immunol Rev* **198**, 169-184
- 38 Nitto, T., Dyer, K. D., Czapiga, M. and Rosenberg, H. F. (2006) Evolution and function of leukocyte RNase A ribonucleases of the avian species, *Gallus gallus*. *J Biol Chem* **281**, 25622-25634
- 39 Huang, Y. C., Lin, Y. M., Chang, T. W., Wu, S. J., Lee, Y. S., Chang, M. D., Chen, C., Wu, S. H. and Liao, Y. D. (2007) The flexible and clustered lysine residues of human ribonuclease 7 are critical for membrane permeability and antimicrobial activity. *J Biol Chem* **282**, 4626-4633
- 40 Schroder, J. M. and Harder, J. (2006) Antimicrobial skin peptides and proteins. *Cell Mol Life Sci* **63**, 469-486
- 41 Conchillo-Sole, O., de Groot, N. S., Aviles, F. X., Vendrell, J., Daura, X. and Ventura, S. (2007) AGGRESCAN: a server for the prediction and evaluation of "hot spots" of aggregation in polypeptides. *BMC Bioinformatics* **8**, 65
- 42 Fan, T. C., Fang, S. L., Hwang, C. S., Hsu, C. Y., Lu, X. A., Hung, S. C., Lin, S. C. and Chang, D. T. (2008) Characterization of molecular interactions between eosinophil cationic protein and heparin. *J Biol Chem* **283**, 25468-25474
- 43 Ulrich, M., Petre, A., Youhnovski, N., Promm, F., Schirle, M., Schumm, M., Pero, R. S., Doyle, A., Checkel, J., Kita, H., Thiyagarajan, N., Acharya, K. R., Schmid-Grendelmeier, P., Simon, H. U., Schwarz, H., Tsutsui, M., Shimokawa, H., Bellon, G., Lee, J. J., Przybylski, M. and Doring, G. (2008) Post-translational tyrosine nitration of eosinophil granule toxins mediated by eosinophil peroxidase. *J Biol Chem*
- 44 Gorr, S. U., Sotsky, J. B., Shelar, A. P. and Demuth, D. R. (2008) Design of bacteria-agglutinating peptides derived from parotid secretory protein, a member of the bactericidal/permeability increasing-like protein family. *Peptides* **29**, 2118-2127
- 45 Fields, G. B. and Noble, R. L. (1990) Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. *Int J Pept Protein Res* **35**, 161-214
- 46 Boix, E., Nikolovski, Z., Moiseyev, G. P., Rosenberg, H. F., Cuchillo, C. M. and Nogues, M. V. (1999) Kinetic and product distribution analysis of human eosinophil cationic protein indicates a subsite arrangement that favors exonuclease-type activity. *J Biol Chem* **274**, 15605-15614
- 47 Yang, J. T., Wu, C. S. and Martinez, H. M. (1986) Calculation of protein conformation from circular dichroism. *Methods Enzymol* **130**, 208-269

FIGURE LEGENDS

Figure 1. Graphical representation of the 3D structure of ECP drawn with Pymol (DeLano Scientific LLC) and ECP primary sequence and its secondary elements drawn with ESPript. The main chains of regions 1-19, 24-45 and 1-45 are labeled in grey tones and the corresponding primary sequence is boxed.

Figure 2. Depolarization activity on *E. coli* (A) and *S. aureus* (B) cells determined by the DiSC₃(5) dye assay. Bacterial cells were grown at 37 °C to mid-exponential phase ($OD_{600} = 0.4$), and resuspended in 5 mM Hepes-KOH, 20 mM glucose, 100 mM KCl, pH 7.2, to an OD_{600} of 0.05. DiSC₃(5) was added and when the dye uptake was maximal, polypeptides in 5 mM Hepes-KOH buffer pH 7.2 were added at a final concentration of 4 μ M. The increase in fluorescence intensity (FI) registers the dye release upon reduction of the transmembrane potential. ECP (circles), ECP(1-45) (triangles), ECP(24-45) (squares) and ECP(1-19) (rhombus). No activity is registered for *S. aureus* cells incubated with ECP(1-19).

Figure 3. Transmission electron microscopy of *E. coli* (left panel) and scanning electron microscopy of *E. coli* (right panel) incubated with 10 μ M of ECP and the peptides for 3 h. From up to bottom: control cells, ECP(1-19), ECP(24-45), ECP(1-45) and ECP. Magnification scale is indicated at the bottom of each micrograph.

Figure 4. Depth-dependent fluorescence quenching profiles calculated by distribution analysis to visualize changes in the Trp chromophore (F) fluorescence, normalized to its value in the absence of quenching (F_0), when the quencher is present at certain depths in the bilayer. h_m is the average location depth of the Trp residues, calculated from the bilayer center. Liposomes containing DOPC/DOPG (3:2) were mixed with increasing molar ratios of (6,7)- Br₂-PC, (9,10)- Br₂-PC, or (11,12)- Br₂-PC. Assay conditions were 0.5 μ M final protein concentration and 200 μ M liposome concentration. ECP(1-19) (closed squares); ECP(24-45) (closed triangles) and ECP(1-45) (closed circles).

Figure 5. Peptide action on lipid bilayers. A) Leakage activity was monitored by release of ANTS/DPX liposome content. Percentage of leakage (% L) produced by the polypeptides after 1 h incubation with liposomes at room temperature was determined. B) LUV aggregation as a function of polypeptide concentration. LUVs were incubated with of each peptide and aggregation was monitored as an increase of scattering intensity at 470 nm at 90° from the excitation beam after 30 min incubation at room temperature. ECP (empty circles), ECP(1-45) (filled squares), ECP(24-45) (filled triangles) and ECP(1-19) (filled circles).

Figure 6. Circular dichroism far UV spectra of ECP (A), ECP(1-19) (B), ECP(24-45) (C), ECP(1-45) (D) in the absence (solid line) and presence of SDS (dotted line) and LPS (dashed line). Four consecutive scans were averaged. Mean-residue ellipticity [θ] ($\text{deg cm}^2 \text{ dmol}^{-1}$) was calculated. Top right insets include the CD near UV spectra in the absence (solid line) and presence (dashed line) of LPS.

Table I. IC₅₀ and minimal inhibitory concentration (MIC) of ECP and peptides. Bacteria were incubated at 37 °C overnight in LB and diluted to give approximately 5x10⁵ CFU/ml. Final values were determined from 2 independent experiments performed in triplicate for each peptide concentration.

Polypeptide	Bactericidal activity (<i>E. coli</i>)		Bactericidal activity (<i>S. aureus</i>)	
	IC ₅₀ (μM)	MIC (μM)	IC ₅₀ (μM)	MIC (μM)
ECP	0.045±0.007	0.30-0.50	0.045±0.004	0.30-0.50
R1R45	0.058±0.009	0.5-0.75	0.060±0.004	0.50-0.75
T24R45	0.282±0.010	5-10	0.173±0.002	1.00-2.00
R1R19	2.866±0.053	50-100	3.579±2.452	50-100

Table II. Maximum position of intrinsic fluorescence spectra of polypeptides in the absence and presence of liposomes, LPS and LTA. Fluorescent emission spectra recorded from 300 to 400 nm using a 280 nm excitation wavelength. The data were fitted with a log-normal function as previously detailed [16]. Quantitative effective displacement values (ED₅₀) for LPS binding, calculated from Fig. 3S curves, are also included. N.D., no displacement is detected.

Polypeptide	Control	DOPC:DOPG 3:2		LPS		LTA		LPS binding
	$\lambda_{\max}$ (nm)	$\lambda_{\max}$ (nm)	λ shift (nm)	$\lambda_{\max}$ (nm)	λ shift (nm)	$\lambda_{\max}$ (nm)	λ shift (nm)	ED ₅₀ (μ M)
ECP	344	339	5	340	4	340	4	0.080 $\pm$ 0.001
R1R45	352	342	10	344	8	342	10	0.780 $\pm$ 0.001
T24R45	355	341	14	346	9	344	11	1.525 $\pm$ 0.004
R1R19	339	336	3	337	2	337	2	N.D.

FIGURES

Figure 1

Figure 2

Figure 3

Figure 4.

Figure 5

Figure 6